OHE Consulting

OHE has published a new report discussing a framework to help middle-income countries efficiently identify medicines for formulary inclusion. A second publication applies this framework to the Mexican decision making system as a case study.

Just published is a new OHE Consulting Report entitled: Four Case Studies to Explore the Added Value of Oxford AHSN. The report provides evidence that the Oxford AHSN is capable of promoting high quality NHS care and delivering projects which improve patient outcomes, at a cost that appears to represent good value for money.

OHE publishes new Consulting Report on shaping the research agenda to estimate relevant cost-effectiveness thresholds for Health Technology Assessment decision making.

A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework.

This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries, and role of HTA in definition of health benefit plans.

It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas.

A new OHE Consulting Report considers the data capabilities in the UK for monitoring medicine use according to indication using real world data.

A new OHE Consulting Report examines whether respondents completing abstract, hypothetical priority-setting exercises in stated preference studies agree with the policy implications of their choices.

Alzheimer’s Research UK commissioned OHE Consulting to model the growing prevalence and costs of dementia in the UK and the impact that new treatments could have were they to be introduced from 2020.

A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value of a new medicine is not likely to be fully known at the time of marketing approval. New uses can expand both the therapeutic and financial value of a particular medicine. In a new study, OHE Consulting seeks to describe and quantify such ‘value expansion’ for a cohort of cancer drugs.

Pages

Subscribe to RSS - OHE Consulting